Kroonen MYAM, et al. – Researchers evaluated whether the plasma concentrations of both atorvastatin and rosuvastatin were associated with LDL-cholesterol and urinary protein to creatinine ratio (UPCR) response in 295 patients. Eligible participants had a UPCR of 500-5000 mg/g and fasting LDL-cholesterol >2.33 mmol/L, and were randomized to a 52-week treatment with atorvastatin 80 mg, rosuvastatin 10 mg or 40 mg. All participants had available samples at week 52 and treatment compliance > 80% by pill count. At week 52, median plasma concentration for atorvastatin 80 mg, rosuvastatin 10 mg and rosuvastatin 40 mg was 3.9 ng/mL, 1.0 ng/mL and 3.5 ng/mL, respectively. Higher statin plasma concentration was related to greater LDL-cholesterol decreases at week 52. Individual variation in rosuvastatin and atorvastatin plasma levels was linked to changes in LDL-cholesterol in patients. The individual variation in UPCR change was not linked to plasma levels of both statins.